Loading
After lutetium therapy stops working, an actinium version of the same drug can still produce responses.
This sequence pairing follows Radioligand therapy (beta emitters) with Targeted alpha therapy using the same targeting molecule: after lutetium stops working, an actinium version of the same drug can still produce responses. Alpha particles cause oxygen-independent clustered DNA damage that beta-resistant, hypoxic or small-volume disease cannot repair, as explained in the Alpha vs beta emitters entry. In Prostate cancer, Actinium-225 PSMA agents after Lutetium-177 vipivotide tetraxetan produced PSA responses in retrospective series, and phase 3 trials (AcTION, AlphaBreak) are ongoing. In Neuroendocrine tumours, Actinium-225 DOTATATE (RYZ101) is being tested in ACTION-1 after Lutetium-177 dotatate, so the evidence is retrospective and phase 1/2 with phase 3 pending.
Shares Actinium-225 PSMA agents, Alpha vs beta emitters, Lutetium-177 vipivotide tetraxetan, Targeted alpha therapy.
Shares Actinium-225 DOTATATE, Actinium-225 PSMA agents, Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Actinium-225 DOTATATE, Lutetium-177 dotatate, Targeted alpha therapy, Neuroendocrine tumours.
Shares Actinium-225 PSMA agents, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Alpha vs beta emitters, Lutetium-177 dotatate, Targeted alpha therapy, Neuroendocrine tumours.
Shares Actinium-225 DOTATATE, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy, Neuroendocrine tumours.
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters), Neuroendocrine tumours.